BioNTech announced new clinical data from its late-stage lung cancer portfolio to be presented at ELCC 2026, highlighting progress across multiple therapeutic approaches.

Updated results for pumitamig, a bispecific immunomodulator, reinforced its efficacy and safety profile, while Phase 3 data for gotistobart showed meaningful survival benefits compared to standard treatments in advanced lung cancer.

The company also emphasized advances in antibody-drug conjugates and mRNA-based therapies, supporting its strategy to develop differentiated, combination-driven treatments across all stages of lung cancer.